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Infusion of Lipoproteins into Volunteers Enhances the Growth of Candida
albicans
Mihai G. Netea, Jo H. A. J. Curfs, From the Departments of Medicine and of Medical Microbiology,
University Hospital Nijmegen, Nijmegen, the NetherlandsPierre N. M. Demacker, Jacques F. G. M. Meis,
Jos W. M. Van der Meer, and Bart Jan Kullberg
Infusion of reconstituted high-density lipoproteins (rHDL) is being studied in clinical trials as an
adjunctive therapy for gram-negative sepsis. Since no data are available on its possible effects in
systemic candidiasis, we investigated the effect of rHDL infusion into volunteers on the growth of
Candida albicans. C. albicans growth was 10- to 100-fold higher in the plasma of volunteers infused
with 80 or 100 mg/kg rHDL than in plasma collected before infusion; administration of 60 mg/kg
rHDL had marginal effects. In vitro, the isolated lipoprotein subfractions had a growth-promoting
effect on C. albicans. These data suggest potential adverse effects of rHDL if infused into patients
with systemic candidiasis. Thus, rHDL infusion into patients with sepsis caused by an unknown
microorganism may be contraindicated.
Despite the availability of new and potent antibiotics, mortal- diasis [6]. In addition, earlier studies have demonstrated that
Candida albicans grows better in lipid-containing emulsionsity from gram-negative bacterial sepsis has remained constant
during the last 30–40 years [1]. The lipopolysaccharide (LPS) used for parenteral feeding than it does in standard preparations
[7–9]. These data suggest that a lipid-rich environment pro-component of the gram-negative bacterial cell wall mediates
most of the inflammatory actions induced by these microorgan- motes C. albicans growth, and this could be a serious drawback
for empirical rHDL treatment. For the present study, we askedisms, and conceptually, its neutralization could have beneficial
effects on the outcome. Recent studies have applied reconstitu- whether rHDL infusion into human volunteers leads to in-
creased candidal growth. In addition, we investigated whetherted high-density lipoproteins (rHDL) for binding and neutral-
ization of LPS. It has been shown that rHDL administered freshly isolated human lipoproteins promote the growth of
C. albicans in vitro and whether C. albicans grows better into animals protects against lethal endotoxemia [2] and gram-
negative sepsis [3]. In addition, its infusion into humans down- plasma of hyperlipoproteinemic mice than in control plasma.
modulates the inflammatory reaction induced by LPS [4]. Be-
cause of these effects, it has been suggested to use rHDL
infusion as an adjunctive therapy in gram-negative sepsis. Materials and Methods
However, sepsis can be caused by a variety of microorganisms,
Infusion of rHDL into human volunteers. Three groups ofincluding gram-negative bacteria, gram-positive bacteria, and
four healthy volunteers each were infused with rHDL at vari-fungi, and on clinical grounds it is often impossible to distin-
ous doses (60, 80, or 100 mg/kg) over a 4-hour period. Bloodguish between these causes. Therefore, it is important to know
samples were collected just before the infusion (time 0) andwhether rHDL infusion would affect the course of sepsis due
4, 12, and 24 hours after the start of the infusion. Plasmato microorganisms other than gram-negative bacteria.
samples from subjects receiving the same dose were pooledAcute disseminated candidiasis is a serious infection, of
at each time point and were provided by Dr. Jan Eva Doranwhich the incidence has increased at least 10-fold during the
and Dr. Alphonse Hubsch (ZLB Central Laboratory, Bern,last decade [5]. We have recently shown that hypercholesterol-
Switzerland).emia in low-density lipoprotein (LDL) receptor–deficient mice
Isolation of the lipoprotein subclasses. LPS-free very-low-increases the susceptibility of these animals to systemic candi-
density lipoprotein (VLDL; final cholesterol concentration, 0.9
mmol/L), LDL (2.0 mmol/L cholesterol), and HDL (0.5
mmol/L cholesterol) subclasses, as well as lipoprotein-depleted
plasma (LPDP) (0.1 mmol/L cholesterol), were isolated byReceived 23 June 1998; revised 8 January 1999.
Informed consent was obtained from all participants, and the guidelines for sequential ultracentrifugation from fresh EDTA-treated plasma
human experimentation of the participating institutions were followed. of healthy volunteers who did not receive rHDL infusion. TheGrant support: Royal Netherlands Academy of Arts and Sciences (to B.J.K.).
methods for isolation of lipoprotein subclasses have been de-Reprints or correspondence: Dr. Bart Jan Kullberg, Department of Medicine
(541), University Hospital Nijmegen, Geert Grooteplein 8, P.O. Box 9101, scribed earlier [10]. Lipoproteins were dialyzed for 24 hours
6500 HB Nijmegen, the Netherlands (B.Kullberg@AIG.AZN.NL). against 0.05 mM phosphate buffer, pH 7.4, containing 5 mM
Clinical Infectious Diseases 1999;28:1148–51 EDTA/L, with one exchange of the buffer. Lipoprotein subfrac-
q 1999 by the Infectious Diseases Society of America. All rights reserved.
1058–4838/99/2805–0032$03.00 tions isolated from six volunteers were studied in triplicate.
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Animals. Homozygous C57BL/6J mice lacking LDL re-
ceptors (LDLR0/0) and wild-type LDLR/// controls were
obtained from Jackson Laboratories (Bar Harbor, ME) as mat-
ing pairs and bred in our local facility. LDL concentrations {
SD in the LDLR0/0 mice were 4.92 { 0.53 mmol/L, com-
pared with 0.35 { 0.11 mmol/L in control LDLR/// mice
[11]. Blood was collected on EDTA from 6- to 8-week-old
mice, and plasma was obtained for the use in C. albicans
growth experiments. LPDP from LDLR0/0 and control ani-
mals was prepared by ultracentrifugation, as described above.
Plasma isolated from five LDLR0/0 and five LDLR/// con-
trol mice was studied in three separate experiments.
C. albicans growth in vitro. C. albicans (American Type
Culture Collection 10231; 104 cfu/mL) was grown in the pooled
plasma of rHDL-infused volunteers, as well as in the various
Figure 1. Growth of Candida albicans in plasma of volunteers
lipoprotein subfractions or lipoprotein-depleted plasma from before and after a 4-hour infusion with reconstituted high-density
untreated volunteers, after 1:1 dilution in Sabouraud broth with lipoproteins (rHDL). Plasma samples were collected from volunteers
before (0 hours) and 4, 12, or 24 hours (h) after infusion with 602% glucose. Similarly, C. albicans (104 cfu/mL) was grown
mg/kg (h), 80 mg/kg (…), or 100 mg/kg (j) rHDL. After 48 hoursin a 1:1 mixture of Sabouraud broth with murine lipoprotein
of incubation, C. albicans grew better in the plasma of volunteerssubfractions or lipoprotein-depleted murine plasma. After 24
who had received 80 or 100 mg/kg rHDL.
and 48 hours of incubation at 377C, aliquots of 40 mL were
plated (Wasp spiral plater; DW Scientific, Shipley, UK) on
Sabouraud dextrose agar. After another 24 hours of incubation infusion rates (4–12 hours) resulted in a significantly increased
outgrowth of C. albicans, compared with the outgrowth of theat 377C, the colonies were counted and the growth was ex-
pressed as the logarithm of colony-forming units per milliliter. yeast in plasma obtained before infusion (P  .05, Kruskal-
Wallis test; data not shown).Comparison between groups was done by use of the Mann-
Whitney test. The Kruskal-Wallis test was used to compare the Growth of C. albicans in freshly isolated human lipoprotein
subclasses. As shown in figure 2A, C. albicans grew bettergrowth curves of C. albicans in depleted and nondepleted mu-
rine plasma. in the lipoprotein emulsions from normal human donors than
in lipoprotein-depleted plasma, suggesting that all lipoprotein
subfractions are able to either enhance C. albicans growth or
Results
to inactivate fungistatic factors present in plasma. To further
investigate these two possibilities, the growth of C. albicansGrowth of C. albicans in plasma of volunteers infused with
rHDL. The total cholesterol and HDL concentrations in the was investigated in plasma of LDLR0/0 mice.
Growth of C. albicans in plasma from hyperlipoproteinemicgroup receiving 60 mg/kg rHDL increased from a basal level
of 3.87 and 0.95 mmol/L, respectively, to 4.63 and 1.03 LDLR0/0 mice. In contrast to plasma collected from human
volunteers, murine plasma inhibited the growth of C. albicansmmol/L at the end of the 4-hour infusion interval and to 4.72
and 1.32 mmol/L at 12 hours and 4.30 and 1.58 mmol/L at 24 in vitro. However, this growth inhibition was significantly re-
duced in plasma from LDLR0/0 mice [6]. After 12 hours ofhours after the start of the infusion. The total cholesterol and
HDL concentrations in the group receiving 100 mg/kg rHDL incubation of 104 cfu of C. albicans in LDLR0/0 plasma, the
log colony count { SD was 3.7 { 1.1, versus 3.2 { 0.9 inincreased from 3.58 and 1.12 mmol/L, respectively, to 4.38
and 1.30 mmol/L at the end of the 4-hour infusion interval and control plasma, and after 24 hours of incubation, it was 3.4 {
1.3, versus 3.0 { 0.7 in control plasma (P  .05). To discernto 5.00 and 1.60 mmol/L at 12 hours and 4.50 and 2.33
mmol/L at 24 hours after the start of the infusion. whether this effect is due to the use of lipoproteins as nutrients
or to the binding and neutralization of a candidacidal factor byThe control growth is represented by the growth of C. albi-
cans in plasma obtained from volunteers before the start of lipoproteins, we compared the growth curves of C. albicans
in lipoprotein-depleted plasma from hyperlipoproteinemic andrHDL infusion (time 0; figure 1). Infusion of 60 mg/kg rHDL
had little effect on the growth of C. albicans, but C. albicans normal mice. C. albicans grew significantly better in lipoprotein-
depleted plasma from LDLR0/0 mice than in lipoprotein-grew better in plasma obtained after infusion of 80 or 100
mg/kg rHDL (figure 1). The number of C. albicans colony- depleted plasma from the LDLR/// controls, although both
subfractions contained similar amounts of lipoproteins (0.01forming units grown in plasma obtained 24 hours after rHDL
infusion was 100-fold greater than that grown in control mmol/L cholesterol) after the depletion procedure (figure 2B).
This suggests that a candidacidal factor may be bound to lipo-plasma. Similarly, infusion of 100 mg/kg rHDL at various
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tein subfractions and in hyperlipoproteinemic plasma from
LDLR0/0 mice. These data are in agreement with our previous
findings in hyperlipoproteinemic LDLR0/0 mice, which were
more susceptible to disseminated candidiasis because of an in-
creased fungal outgrowth in their organs [6]. Although lipid
profiles differ between mice and humans, the results of both
studies suggest that hyperlipidemia can have deleterious effects
by stimulating C. albicans growth in both species.
At least two different mechanisms seem to be responsible
for the observed effects. First, in agreement with other reports
showing increased growth of C. albicans in lipid emulsions
used for parenteral feeding [7, 8], lipids themselves seem to
promote the growth of Candida. Cholesterol may act as a nutri-
ent for C. albicans, as has been demonstrated for other microor-
ganisms, such as Staphylococcus aureus [12]. After infusion
of rHDL, natural HDL has to be formed through extraction of
cholesterol from cell membranes and other lipoprotein subfrac-
tions, since rHDL consists of phospholipids and recombinant
apolipoprotein A-1 without cholesterol [2]. This process re-
quires several hours, and this explains the increasing effect of
rHDL on C. albicans growth at later time points after infusion.
Indeed, the total cholesterol and HDL concentrations were
found to be higher 12 and 24 hours after the start of the infusion
than at the end of the 4-hour infusion interval.
Second, since the growth of C. albicans was enhanced in
lipoprotein-depleted plasma of hyperlipoproteinemic mice,
binding and neutralization of candidacidal factors, such as
sphingosine [13], platelet microbicidal protein [14], or the cal-
protectin complex [15], by lipoproteins may contribute to the
observed effect. Although no lipoproteins were present in lipo-
protein-depleted plasma isolated from either LDLR0/0 or nor-Figure 2. In vitro growth of Candida albicans in the presence of
lipoproteins. A, C. albicans grows better in plasma containing freshly mal mice, C. albicans growth was significantly increased in
isolated very-low-density lipoproteins (VLDL), low-density lipopro- lipoprotein-depleted plasma from LDLR0/0mice, from which
teins (LDL), or high-density lipoproteins (HDL), diluted 1:1 in Sa- five-fold more lipoproteins had been extracted. This suggests
bouraud broth, than in lipoprotein-depleted plasma (LPDP). B,
that a candidacidal factor associates with lipoproteins, and be-C. albicans grows significantly better in LPDP from mice lacking
cause of this binding, the candidacidal effects of plasma mayLDL receptors (l) than in that from control mice (j). Each point
represents mean { SD of 5 experiments. * P  .05 (Kruskal-Wallis decrease. Indeed, it has been reported that cholesterol is able
test). to inhibit the candidastatic capacity of sphingosine [13]. Asso-
ciation of an antimicrobial factor with HDL has been reported
for S. aureus [16], and this may also explain the differences
observed between HDL and VLDL effects on C. albicansproteins and extracted together with lipoproteins during the
lipoprotein depletion procedure. growth, despite the higher cholesterol content of the VLDL
subfraction (figure 2A).
Infusion of rHDL as adjunctive therapy for presumed gram-
Discussion
negative infections is currently under investigation in clinical
trials. Although infusion with a moderate rHDL regimen (60The results of the present study show that rHDL infusion (at
⁄80 mg/kg) increases the growth of C. albicans in the plasma mg/kg) seems to have no significant effects on C. albicans
growth, higher quantities of rHDL strongly potentiate growth ofof human volunteers by 10- to 100-fold, compared with the basal
growth curve in their plasma collected before rHDL administra- these organisms. This suggests that rHDL may have significant
adverse effects when infused into patients with systemic candi-tion. In contrast, there was no significant difference in the growth
of C. albicans in plasma before and after infusion of a moderate diasis, and infusion with rHDL into patients with sepsis caused
by an unknown microorganism may be contraindicated. In ad-amount of rHDL (60 mg/kg). Similarly, C. albicans growth was
increased in the presence of freshly isolated human lipopro- dition, it has been suggested that a lipid-rich environment po-
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